On November 14, 2023, Eterna Therapeutics Inc. (Company) entered into an Exclusive Amended and Restated License Agreement (A&R Agreement) with Factor Bioscience Limited (Factor) to replace in its entirety the Exclusive License Agreement dated February 20, 2023, as amended on July 12, 2023. The A&R Agreement provides for, among other things, the expansion of the Company?s license rights to include (i) know-how that is necessary or reasonably useful to practice to the licensed patents and (ii) the ability to sublicense through multiple tiers (as opposed to only permitting a direct sublicense). The A&R Agreement also provides for technology transfer to Eterna, subject to the use restrictions in the A&R Agreement and reduces the termination rights of Factor under the A&R Agreement.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.04 USD | +2.51% | +0.49% | +13.65% |
1st Jan change | Capi. | |
---|---|---|
+13.65% | 10.77M | |
+62.59% | 62.59B | |
-1.82% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.38% | 26.21B | |
-22.03% | 19.09B | |
+4.17% | 13.08B | |
+25.55% | 12.26B | |
+27.83% | 12.05B |
- Stock Market
- Equities
- ERNA Stock
- News Eterna Therapeutics Inc.
- Eterna Therapeutics Inc. Enter into an Exclusive Amended and Restated License Agreement with Factor Bioscience Limited